Loading...
Market
Will the acquisition of Proteologix by Johnson & Johnson be approved by regulatory bodies by the end of 2024?
5
Resolution / Starting Odds
Approved • 50%
Not Approved • 50%
public announcements from regulatory bodies
Story
Johnson & Johnson to Acquire Proteologix for $850 Million, Including Dual-Targeting Antibody Drugs
May 16, 2024, 12:25 PM
Johnson & Johnson announced on Thursday that it will acquire privately held Proteologix for $850 million in cash, with potential for an additional milestone payment. The acquisition aims to bolster Johnson & Johnson's leadership in the treatment of atopic dermatitis. Proteologix brings a young roster of bispecific immunology medications, including a phase 1-ready asset targeting TSLP and dual-targeting antibody drugs. The acquisition has seen Johnson & Johnson's stock (JNJ) rise by 0.1% in pre-market trading.
View original story
Similar markets
Standalone Unit • 25%
Merged with J&J Immunology Division • 25%
Merged with J&J Research and Development • 25%
Dissolved with Assets Redistributed • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Approved without conditions • 33%
Approved with conditions • 33%
Not approved • 33%
